Suliman Sara, Ellaithi Mona
Department of Histopathology and Cytology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan.
Prostate Cancer. 2024 Dec 22;2024:4406057. doi: 10.1155/proc/4406057. eCollection 2024.
Prostate cancer is the most common noncutaneous malignancy among men worldwide, including in Sudan, where it represents a significant public health challenge. CD147, a transmembrane glycoprotein implicated in tumor progression, invasion, and metastasis, has shown potential as a prognostic biomarker in various cancers. This retrospective case-control study aimed to evaluate CD147 expression in prostate adenocarcinoma among Sudanese men and its association with tumor grade. A total of 80 paraffin-embedded tissue samples, including 40 cases of prostate adenocarcinoma and 40 benign prostatic hyperplasia (BPH) controls, were analyzed using immunohistochemistry. CD147 expression was observed in 22.5% of adenocarcinoma cases compared to 7% of controls; however, the association was not statistically significant (=0.07). Low-grade tumors were predominant in the cohort, consistent with early-stage diagnoses. The findings revealed no clear link between CD147 expression and tumor grade, diverging from prior studies that associate CD147 with advanced tumor stages. The nonsignificant results may be attributed to the small sample size, emphasizing the need for future research with larger, more diverse cohorts, advanced molecular techniques, and functional studies to better elucidate the role of CD147 in prostate cancer pathogenesis and its potential as a therapeutic target.
前列腺癌是全球男性中最常见的非皮肤恶性肿瘤，在苏丹也是如此，它是一项重大的公共卫生挑战。CD147是一种跨膜糖蛋白，与肿瘤进展、侵袭和转移有关，已显示出作为各种癌症预后生物标志物的潜力。这项回顾性病例对照研究旨在评估苏丹男性前列腺腺癌中CD147的表达及其与肿瘤分级的关联。使用免疫组织化学分析了总共80个石蜡包埋组织样本，包括40例前列腺腺癌病例和40例良性前列腺增生（BPH）对照。腺癌病例中22.5%观察到CD147表达，而对照中为7%；然而，这种关联无统计学意义（P=0.07）。该队列中低级别肿瘤占主导，与早期诊断一致。研究结果显示CD147表达与肿瘤分级之间没有明确联系，这与之前将CD147与晚期肿瘤阶段相关联的研究不同。结果无统计学意义可能归因于样本量小，这强调了未来需要进行更大、更多样化队列的研究、先进的分子技术和功能研究，以更好地阐明CD147在前列腺癌发病机制中的作用及其作为治疗靶点的潜力。
